THEVAX GENETICS VACCINE CO., LTD.

Update：2025/12/24

Industries

Biotechnology Biopharma Genetics Medical Oncology Therapeutics

Add to Favorites Edit

About

Financials

Patent

News

Main Industry

Biotechnology

Founded Year

2012

Unified Business No.

53778660

Status

Active

Number of Employees

Total Paid-in Capital

1,028,500,000 (NT$)

Location of Company

Taiwan , Taipei City

Website

Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.

Exclusive content for members

Members-only content. Please log in to access.

Similar Companies

Great Novel Therapeutics Biotech & Medicals Corporation

GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.

Biotechnology Biopharma Medical Oncology Pharmaceutical Therapeutics

AP BIOSCIENCES INC.

Biotechnology Biopharma Medical Oncology Pharmaceutical Therapeutics

Rephlmmune Biotechnology Inc.

RephImmune is pioneering a new frontier in cancer immunotherapy with its proprietary platform, Reconstitute-Immunity Antigen-Cell Engager (RACE). This cutting-edge technology is rooted in regeneration biology and is specifically designed to reprogram and

Biotechnology Biopharma Genetics Oncology Therapeutics

ARCE THERAPEUTICS, INC.

ARD103
ANTI-CLL1 auto-CAR-T
ARD103, our priority product, is an autologous CAR-T cell manufactured by DashCAR® technology with an ultra-fast processing time and stem cell-like phenotypes. ARD103 specifically targeted C-type lectin-like molecule-1 (CLL-1)

Biotechnology Biopharma Genetics Oncology Therapeutics